Reaching Critical Mass: Taking Stock of Stakeholders’ Fears During a Crisis

When a patient died during a clinical trial last year, Targeted Genetics, a publicly traded biotech company based in Seattle, found itself in a tailspin as it dealt with a

flurry of negative media attention, scrutiny from industry groups and a huge drop in stock price.